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Clear-lens extraction as a treatment for primary angle closure 
Glaucoma is a multifactorial spectrum of diseases 
in which progressive optic nerve damage leading to 
blindness occurs with raised intraocular pressure as 
the main risk factor. The outﬂ ow of ﬂ uids through the 
trabecular meshwork decreases when the iris moves 
forward and comes into contact with it. This condition 
is called “angle closure” and can lead to glaucoma 
damage if intraocular pressure remains suﬃ  ciently 
raised. When no other cause besides anatomical 
predisposition is present for the iridotrabecular 
contact, the condition is classiﬁ ed as primary angle 
closure, and if glaucomatous optic neuropathy 
is present it is classiﬁ ed as primary angle-closure 
glaucoma. The reported prevalence varies because of 
heterogeneity in deﬁ nitions of primary angle-closure 
glaucoma and methods of angle assessment used in 
diﬀ erent surveys.1 Even more common than primary 
angle closure and primary angle-closure glaucoma is 
primary open-angle glaucoma. These three disorders 
have similarities, such as increasing prevalence after 
improvement, readily equalled by patients not so 
mobilised in the weeks after hospital discharge.
Far less is known about these later eﬀ ects of early 
mobilisation, whether provided by an additional 
physical therapist or by more eﬀ ective coordination and 
communication of existing resources. Regrettably, the 
International Early SOMS-guided Mobilisation Research 
Initiative achieved only 42% (84 of 200 patients) 
follow-up at 3 months. Such low ﬁ gures at follow-
up are not uncommon in ICU RCTs, although not 
universal.6 A full endorsement of early mobilisation 
must wait for more data, even as many pragmatically 
attempt early mobilisation based on the hope that 
its eﬀ ects on trajectory are durable. Large trials7 of 
mobilisation in other patient groups provide caution to 
making assumptions about its long-term beneﬁ t.
The future of early mobilisation research must move 
beyond the ICU and must include randomised tests 
of the hypothesis that early mobilisation provides 
enduring improvements for patients. Additionally, 
future research must go beyond the question of no 
mobilisation or some mobilisation. At some point—
which will need more than 200 patients to be achieved—
the diﬀ erent strategies for mobilisation need to be 
compared. These diﬀ erent strategies should include not 
only diﬀ erent speciﬁ c regimes of active exercise, but 
also diﬀ erent approaches to integrate active exercise in 
the core interdisciplinary teamwork of the ICU. Use of 
these strategies will need use of all the tools of quality 
improvement, both RCTs and registries. Patients who 
are at particularly high risk for adverse outcomes of 
mobilisation need to be identiﬁ ed, cognizant of the 
non-signiﬁ cant diﬀ erence in mortality seen in Schaller 
and colleagues’4 and other RCTs. Furthermore, an 
understanding is needed of how early mobilisation 
can be integrated into coherent programmes of before 
ICU, in the ICU, and after ICU care to mitigate the post-
intensive care syndrome, maximising recovery for all 
critically ill patients.
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age 50 years, but also striking diﬀ erences, such as the 
increased frequency of primary angle closure in some 
ethnic groups.2
Due to increased life expectancy and demographic 
expansion, the number of glaucoma cases worldwide 
is estimated to reach 76 million by 2020, of which 
23 million will be primary angle-closure glaucoma.3 
The established initial treatment for primary angle 
closure and primary angle-closure glaucoma is laser 
iridotomy with eye drops to reduce intraocular 
pressure. In the past decade, lens extraction (both clear 
or with cataract) with intraocular lens implantation 
has gained popularity due to good results in series of 
patients with various primary types of angle closure 
based on diﬀ erent deﬁ nitions and anecdotal evidence.4 
Technological advances in surgical techniques have 
also improved the safety of phacoemulsiﬁ cation in 
patients with glaucoma. Lens extraction either clear 
or with cataract to treat primary angle closure, judged 
on an individual basis, has also been recommended 
by guidelines.4
Augusto Azuara-Blanco and colleagues5 report in 
The Lancet the results of an international prospective 
randomised study comparing laser iridotomy with 
clear-lens extraction as the initial treatment of 
primary angle closure and primary angle-closure 
glaucoma. This is also the ﬁ rst prospective randomised 
therapeutic trial in ophthalmology in which one of 
the primary outcome measures is patient reported, 
through quality-of-life questionnaires. The co-
primary endpoints were patient-reported health 
status, intraocular pressure, and incremental cost-
eﬀ ectiveness ratio per quality-adjusted life-year 
gained 36 months after treatment. 419 patients 
were randomised and followed up for 3 years, of 
whom 208 were assigned to clear-lens extraction 
and 211 to laser iridotomy. 351 (84%) had complete 
data on health status and 366 (87%) on intraocular 
pressure. The results show a small but unquestionable 
advantage of primary clear-lens extraction over laser 
iridotomy for all measured outcomes. The mean health 
status score (0·87 [SD 0·12]) on the European Quality 
of Life-5 Dimensions (EQ-5D) questionnaire, was 0·052 
higher (95% CI 0·015 to 0·088, p=0·005) and mean 
intraocular pressure (16·6 [SD 3·5] mm Hg) 1·18 mm 
Hg lower (95% CI –1·99 to –0·38, p=0·004) after clear-
lens extraction than after iridotomy. The incremental 
cost-eﬀ ectiveness ratio was £14 284 for initial lens 
extraction versus standard care, although the costs 
were assessed only for the subset of patients treated 
in the UK and, therefore, are not conclusive for other 
settings. 
This pragmatic trial is clinically relevant because 
it addresses a topic with widespread practical 
implications. Patients undergoing clear-lens extraction 
became emmetropic (ﬁ nal refraction 0·08 [SD 0·95]), 
whereas those assigned to laser iridotomy remained 
hyperopic (0·92 [2·8]). Uncorrected visual acuity, 
therefore, improved greatly for distance and near 
vision in the clear-lens extraction group only, which 
was associated with improvements in patient-
reported outcome questionnaires. How this purely 
refractive result aﬀ ected the observed improvement 
in the clear-lens extraction group compared with the 
laser iridotomy group (a change in absolute terms of 
almost 6% for the EQ-5D, 7% for the Glaucoma Utility 
Index, and 2·58% for the National Eye Institute Visual 
Function Questionnaire-25) remains to be determined. 
The clinical relevance of the small diﬀ erence between 
groups in intraocular pressure (1·18 mm Hg) is unclear 
since patients with advanced glaucoma damage were 
excluded from the study. The use of eye drops to lower 
intraocular pressure, however, was less in the clear-lens 
extraction group than in the laser iridotomy group 
(mean 0·4 [SD 0·8] vs 1·3 [1·0]). This ﬁ nding partly 
explains the small diﬀ erence recorded for intraocular 
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in the need for further surgery to control intraocular 
pressure (one patient in the clear-lens extraction 
group vs 24 patients in the laser iridotomy group); of 
the 24 patients in the laser iridotomy group who had 
further surgery, 16 (67%) underwent cataract surgery. 
However, the need for some cataract operations within 
3 years is not surprising and this ﬁ nding should not 
to be interpreted as an increased occurrence of an 
unfavourable outcome in the laser iridotomy group.
Cataract extraction by phacoemulsiﬁ cation causes 
continued progressive endothelial cell loss,6,7 and 
increasing age is associated with decreasing endothelial 
cell counts.8 The mean corneal endothelial cell loss 
after phacoemulsiﬁ cation in patients whose eyes 
have shallow anterior chambers and short axial 
lengths—both features of primary angle closure—is 
around 19%.9 Azuara-Blanco and colleagues5 did not 
address corneal endothelial cell loss, possibly because 
such an assessment is not always part of the routine 
preoperative preparation for phacoemulsiﬁ cation in 
most centres.
Primary angle closure and primary angle-closure 
glaucoma are very diﬀ erent disorders, especially 
according to the deﬁ nitions used by Azuara-Blanco 
and colleagues. They noted that their results are 
applicable only to patients with primary angle closure 
and intraocular pressure greater than 30 mm Hg—who 
represent a minority of patients with this disorder—or 
to those with primary angle-closure glaucoma without 
advanced damage, implying that these two groups 
would be expected to respond to treatment in a similar 
way. However, how generalisable the study’s ﬁ ndings 
are to other patients remains elusive. 
Phacoemulsiﬁ cation to treat primary angle 
closure can be technically challenging. The surgeons 
involved in Azuara-Blanco and colleagues’ study 
were highly experienced. Training for routine cataract 
surgery might not provide the skills needed to reach 
consistently good results for phacoemulsiﬁ cation 
clear-lens extraction in primary angle closure cases that 
would achieve the safety margin and avoid the few 
but potentially severe intraoperative complications 
reported in this study, and less experienced surgeons 
might incur more diﬃ  culties and complications. 
Nevertheless, the study highlights the great advances 
made in phacoemulsiﬁ cation techniques. 
While not yet suﬃ  cient to justify using clear-lens 
extraction to treat all patients with primary angle 
closure with or without glaucoma, the ﬁ ndings of this 
trial could have positive implications for areas where 
angle closure is most prevalent, particularly east 
Asia,3 or where health-care resources are scarce and 
patients might not have easy access to medications 
and monitoring. A not yet proven potential additional 
beneﬁ t with clear-lens extraction is that early 
intervention might prevent blindness due to primary 
angle-closure glaucoma. The ﬁ ndings of Azuara-Blanco 
and colleagues underline the need for further eﬀ orts 
to improve phenotyping of angle closure and for more 
randomised prospective therapeutic trials that include 
other subtypes of primary angle closure and assess the 
eﬀ ects of laser iridotomy in eyes with narrow but not 
yet closed angles. 
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